ALTASCIENCES
5.5.2021 19:01:05 CEST | Business Wire | Press release
Altasciences , a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories , a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA . For more than 40 years, Calvert Laboratories has been working with clients to help develop the next generation of therapeutics aimed at extending and improving human life; in line with Altasciences’ focus on getting better drugs to the people who need them faster.
“This acquisition will increase small molecule expertise as well as add efficacy pharmacology, ophthalmology, and carcinogenicity study capabilities, to Altasciences’ current preclinical offering. Furthermore, it expands Altasciences’ presence on the East Coast, and the site is conveniently located in close proximity to our CDMO facility ,” added Steve Mason, Co-Chief Operating Officer at Altasciences.
Calvert Laboratories has a long track record in the industry as a collaborative development partner bringing extensive experience, an innovative solutions-oriented approach, and unsurpassed performance to preclinical drug development programs. “The entire team at Calvert Laboratories is very excited to join the Altasciences family,” said Michael A. Recny, Ph.D., outgoing Chief Executive Officer of Calvert Laboratories. “The Company can now offer our clients an expanded suite of preclinical and clinical services by leveraging the broad capabilities of a larger and more diversified global CRO. ”
“This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution, while addressing the ever-changing outsourcing challenges of biopharmaceutical companies across the globe, ” explained Chris Perkin, CEO at Altasciences. “We look forward to working side by side with our new team of preclinical experts on the East Coast, a team that shares our values for excellence, integrity, and customer focus,” concluded Chris Perkin.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005913/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 202611.8.2026 11:00:00 CEST | Press release
Recognition highlights the MultiBank Group Founder and Chairman’s leadership, global experience and contribution to the financial services industry MultiBank Group, one of the world’s largest and most regulated financial derivatives institutions, has announced that its Founder and Chairman, Naser Taher, has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811229836/en/ Naser Taher has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. The annual Forbes Middle East Top 100 CEOs list celebrates prominent business leaders who are shaping the region’s corporate landscape and leading organisations with significant scale, influence and impact. The ranking brings together
teamLab Unveils New Series from Light Sculpture - Flow at teamLab Borderless. Special Exhibit, "On the Asymmetry of the Universe," on View Through October 811.8.2026 11:00:00 CEST | Press release
teamLab reopens the Light Sculpture - Flow series artwork space at teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Azabudai Hills, Tokyo from July 8, 2026. To commemorate the reopening, teamLab unveils two new series, Asymmetric Existence and Chromatic Existence, featured in the special exhibit "On the Asymmetry of the Universe." The special exhibit, “On the Asymmetry of the Universe,” runs from Wednesday, July 8, 2026 through Thursday, October 8, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807256066/en/ Light Sculpture - Flow The inside and outside of an ocean vortex are composed of the same water; there is no material difference between them. Yet, despite this, why do we perceive a vortex as a singular entity, or even sense a form of life within it? The difference between the inside and outside of a vortex lies in the order, not the material. When order is born within a flow, existence emerges even with
KIOGE 2026 Marks 30 Years of Connecting the Global Energy Industry with Central Asia11.8.2026 10:21:00 CEST | Press release
30 September – 2 October 2026 As Kazakhstan strengthens its position as one of Eurasia's leading energy markets, KIOGE 2026 – the 30th Kazakhstan International Oil & Gas Exhibition and Conference – invites international companies to explore business opportunities and establish partnerships across Central Asia's evolving oil and gas sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811699632/en/ Almassadam Satkaliyev, Minister of Energy of the Republic of Kazakhstan in 2024, speaking at KIOGE (Photo: AETOSWire) For three decades, KIOGE has connected global manufacturers, technology providers, EPC contractors, service companies and investors with key decision-makers shaping Kazakhstan's energy industry. For companies entering the market or expanding their regional presence, the event provides direct access to one of Central Asia's most significant energy economies. KIOGE 2026 has already attracted more than 235 compani
Cambridge International AS & A Level Entries Grow 5% Amid Rising Higher Education Demand for Flexible, Skills-Based Qualifications11.8.2026 08:03:00 CEST | Press release
Around 368,000 Cambridge International AS & A Level students receive results todayNearly 705,000 students in 148 countries sat Cambridge exams in the June series, with total entries up to 1.7 million Cambridge International Education (Cambridge) has begun releasing the results of its June 2026 exam series to students worldwide. Entries for Cambridge International AS & A Levels rose 5% on last year, with almost 368,000 students in 3492 schools worldwide receiving Cambridge International AS & A Level results today. This continued growth reflects the increasing global demand for qualifications that provide a trusted route to higher education. Recognised by more than 2500 universities worldwide, Cambridge International AS & A Levels equip learners with the academic knowledge, independent thinking and problem-solving skills needed to succeed at university and beyond. Their acceptance now extends well beyond traditional destinations such as the UK, the US, Canada and Australia, with leading
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release
Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
